Up a level |
Pettitt, AR, Polydoros, F, Dodd, J, Oates, M, Lin, K, Kalakonda, N, McCarthy, H, Bloor, A, Schuh, A, Duncombe, A et al (show 6 more authors)
(2016)
FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL).
.
Parker, H, Rose-Zerilli, MJJ, Larrayoz, M, Clifford, R, Edelmann, J, Blakemore, S, Gibson, J, Wang, J, Ljungstrom, V, Wojdacz, TK et al (show 28 more authors)
(2016)
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
Leukemia, 30 (11).
pp. 2179-2186.
Eagle, GL ORCID: 0000-0002-7381-2355, Zhuang, J ORCID: 0000-0003-3245-0789, Jenkins, R, Kitteringham, N, Oates, M, Park, K, Schuh, A, Devereux, S, Hillmen, P and Pettitt, A
(2016)
LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE.
.
Eyre, TA, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, GP, Devereux, S, Follows, G, Fox, CP et al (show 12 more authors)
(2016)
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
BRITISH JOURNAL OF HAEMATOLOGY, 175 (1).
pp. 43-54.